The present invention provides a method for curing Parkinsons disease through regulating VDAC1 (voltage-dependent anion channel 1) protein. Specifically, the present invention provides a pharmaceutical composition for curing PD comprising a VDAC1 protein regulator. The VDAC1 protein regulators comprise an inhibitor of VDAC1 mRNA production, an inhibitor of mitochondrial permeability transition pore (mPTP) formation, and a mitochondrial calcium uptake inhibitor. In addition, the present invention provides a method for curing Parkinsons disease comprising administering a VDAC1 protein regulator to a subject with Parkinsons disease. The present invention could provide a method for curing Parkinsons disease through preventing and/or restoring mitochondrial dysfunction.
